Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00651690 · ClinicalTrials.gov registry record · Phase 2
Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke Upper Limb Spasticity With Botulinum Toxin Type A Treatment
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00651690 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 62 participants.
The verdict
NCT00651690, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
This study evaluates the responsiveness of 7 functional tasks to botulinum toxin Type A treatment in poststroke patients with spasticity of the upper-limb flexors
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Botulinum Toxin Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00651690
The ClinicalTrials.gov registry entry for NCT00651690 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00651690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00651690 about?
NCT00651690 is a clinical study titled "Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke Upper Limb Spasticity With Botulinum Toxin Type A Treatment". This study evaluates the responsiveness of 7 functional tasks to botulinum toxin Type A treatment in poststroke patients with spasticity of the upper-limb flexors
What is the current status of trial NCT00651690?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2004-03. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00651690?
The interventions under investigation include: Placebo (BIOLOGICAL), Botulinum Toxin Type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT00651690?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.